Navigation Links
Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer
Date:9/25/2007

VIENNA, Austria, September 25 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, today announced the appointment of Dr. Geert Mudde as Chief Scientific Officer. Dr. Mudde has over 20 years of experience in the biotech and pharmaceutical industry, specializing in preclinical research and development. He comes to f-star from Baxter BioScience, where he was Director of Discovery Research and Technical Assessment.

"Geert brings in a wealth of knowledge and experience in industrial research and development which will be of prime importance in shaping f-star's proprietary product development programs. We are delighted that he joins the executive management team at such a decisive stage of the Company's development," said Dr. Gottfried Himmler, CEO f-star.

"f-star has now established its proprietary Modular Antibody Technology as a unique antibody engineering technology with an excellent IP position. Based on the recent financing the Company is now prepared to move to the next stage and define its own development programs," said Dr. Geert Mudde, CSO. "I am excited to contribute to this important development step as part of the executive team," he added.

Dr. Mudde was one of the founders of f-star in 2006 and worked as a consultant to the Company since then. Prior to his most recent position at Baxter BioScience he held senior-level positions in the international biotechnology and pharmaceutical industry, including VP Research at Igeneon, Austria, Director Immunology at Ingenium Pharmaceuticals, Germany, and Director of Allergy & Inflammation/Immunology at Parke Davis in Paris, France. Before that he worked at Sandoz/Novartis and at the Swiss Institute for Allergy Research. Dr. Mudde received his PhD in immunology from the University Utrecht (The Netherlands).

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The Company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, antibody fragments with antibody functionality and long half-life but much smaller size (Fcab(TM)) or full antibodies with additional functionality (mAbsquared) can be created.

The Company was founded by a team of experienced antibody engineering and biotech executives. Seed-financed by Austrian government agencies and Atlas Venture in 2006, the Company recently closed a Series A financing round co-led by Aescap Venture and Atlas Venture and has raised EUR 10.0m so far. f-star has 15 employees at its research site in Vienna, Austria.

For more information, visit http://www.f-star.com

Company contact:

Dr. Eugen Stermetz

CFO

f-star Biotechnologische Forschungs- und Entwicklungs-GmbH

+43-1-230-60-30-45

Muthgasse 18

A-1190 Vienna, Austria

http://www.f-star.com

Media contact:

Frank Butschbacher

Investor Relations & Communications

+43-650-78-44-940

office@butschbacher.net

http://www.butschbacher.net


'/>"/>
SOURCE f-star
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Detection of antibody-stained cell surface and intracellular protein targets with the Agilent 2100 bioanalyzer
2. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
3. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
4. Biomedical engineering conference invites manufacturers
5. Re-engineering our economy to be sustainable and profitable
6. UW Biomedical Engineering awarded $2.9 million research grant
7. 3M donates $1.6 million to UW-Madison engineering building
8. Social engineering - Coming to an IT ship near you?
9. UW engineering career fair sees highest attendance in four years
10. Appleton engineering firm gets $250,000 in tax credits to build facility
11. UW-M engineering dean heads for promising medical business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... Martinsried, Germany (PRWEB) , ... July 14, 2017 ... ... developed standardized solution for sample preparation of proteins to clean peptides for mass ... Bioruptor® sonication system. , The PreOmics iST Kit is based on proprietary ...
(Date:7/13/2017)... KANSAS CITY, MISSOURI (PRWEB) , ... July 13, ... ... it has earned URAC accreditation in Specialty Pharmacy. URAC is the independent leader ... Heritage Biologics has demonstrated a comprehensive commitment to quality care, improved processes and ...
(Date:7/13/2017)... , ... July 13, 2017 , ... ... two spectrophotometer calibration standards. Blast forward seven years and now they are ... holmium oxide for wavelength accuracy, and resolution testing. , ...
(Date:7/13/2017)... ... July 13, 2017 , ... ... at Philadelphia’s University City Science Center, Christopher Laing, MRCVS, Ph.D. has been tapped ... Texas. Dr. Laing will become the first Executive Director at the newly ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):